StreetInsider.com News Articles

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

ATLANTA, July 8, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living with myasthenia gravis (MG) or supporting a loved one impacted by the disease. The scholarship program reflects UCB's continued commitment to supporting the MG community beyond medicine by helping reduce the financial burden associated with pursuing higher education and career development.

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Wed, 08 Jul 2026 09:02:00 -0400

UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Berenberg

Thu, 02 Jul 2026 05:06:01 -0400

Berenberg analyst Diana H W Na raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR290.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Berenberg

Thu, 02 Jul 2026 05:06:01 -0400

Berenberg analyst Diana H W Na raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR290.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Berenberg

Thu, 02 Jul 2026 05:06:01 -0400

Berenberg analyst Diana H W Na raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR290.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Berenberg

Thu, 02 Jul 2026 05:06:01 -0400

Berenberg analyst Diana H W Na raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR290.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Lowered to EUR320 at UBS

Mon, 22 Jun 2026 08:21:34 -0400

UBS analyst Xian Deng lowered the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR320.00 (from EUR330.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Lowered to EUR320 at UBS

Mon, 22 Jun 2026 08:21:34 -0400

UBS analyst Xian Deng lowered the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR320.00 (from EUR330.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Lowered to EUR320 at UBS

Mon, 22 Jun 2026 08:21:34 -0400

UBS analyst Xian Deng lowered the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR320.00 (from EUR330.00) while maintaining a Buy rating.

UCB (UCB:BB) (UCBJY) PT Lowered to EUR320 at UBS

Mon, 22 Jun 2026 08:21:34 -0400

UBS analyst Xian Deng lowered the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR320.00 (from EUR330.00) while maintaining a Buy rating.

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

ATLANTA, June 17, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³